Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H-1337 Phase 2b in POAG and Ocular Hypertension
NCT05913232Phase 2Completed
- Sponsor
- D. Western Therapeutics Institute
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of H-1337 in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by D. Western Therapeutics Institute. Started Aug 2023; status: completed.
02
Drugs
H-1337
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT05913232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05913232.